BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38381045)

  • 1. Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway.
    Weatherdon L; Stuart K; Cassidy M; de la Gándara AM; Okkenhaug H; Muellener M; Mckenzie G; Cook SJ; Gilley R
    Biochem J; 2024 Mar; 481(6):405-422. PubMed ID: 38381045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
    Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ
    Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
    Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
    Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.
    Lochhead PA; Clark J; Wang LZ; Gilmour L; Squires M; Gilley R; Foxton C; Newell DR; Wedge SR; Cook SJ
    Cell Cycle; 2016; 15(4):506-18. PubMed ID: 26959608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
    Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
    Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.
    Kidger AM; Sipthorp J; Cook SJ
    Pharmacol Ther; 2018 Jul; 187():45-60. PubMed ID: 29454854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
    J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
    Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
    Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
    Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
    Sale MJ; Cook SJ
    Br J Pharmacol; 2013 Aug; 169(8):1708-22. PubMed ID: 23647573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.
    Jameson KL; Mazur PK; Zehnder AM; Zhang J; Zarnegar B; Sage J; Khavari PA
    Nat Med; 2013 May; 19(5):626-630. PubMed ID: 23603816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.